ADAR1 Capital Management’s ZyVersa Therapeutics ZVSA Stock Holding History

ADAR1 Capital Management’s Portfolio ZVSA Stock Details ZVSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-9,598	Closed	-$36.1K	–	353
2024 Q2	$36.1K	Buy	+9,598	New	+$51.5K	0.01%	202

Other funds holding ZVSA

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ADAR1 Capital Management's ZVSA Position: Q3 2024 in Review

ADAR1 Capital Management sold out of ZyVersa Therapeutics (ZVSA) in Q3 2024, closing a stake of 9,598 shares — an estimated $36.1K sold.

ADAR1 Capital Management first reported a position in ZVSA in Q2 2024 and held it in 1 quarter. The position peaked at $36.1K in Q2 2024. 6 funds tracked by Wall St. Rank hold ZVSA as of Q3 2024.

ADAR1 Capital Management reported no remaining ZyVersa Therapeutics position as of Q3 2024 after selling out during the quarter.
ADAR1 Capital Management sold 9,598 ZyVersa Therapeutics shares in Q3 2024, an estimated $36.1K.
ADAR1 Capital Management first reported a position in ZyVersa Therapeutics in Q2 2024 and held it in 1 quarter.
ADAR1 Capital Management's ZyVersa Therapeutics position peaked at $36.1K in Q2 2024.
6 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q3 2024.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.